Forum Médical Suisse
Forum Medico Svizzero
Schweizerisches Medizin-Forum
Swiss Medical Forum

Myasthenia gravis und myasthene Syndrome – Update

Teil 2: Therapie

Myasthénie et syndromes myasthéniques – Update

2e partie: traitement

Literatur / Références

1. Hohlfeld R, Melms A, Schneider K, Toyka KV, Drachman DB. Therapy of myasthenia gravis and myasthenic syndromes. In: Neurological Disorders: Course and Treatment (eds.T. Brandt, Caplan LR, Dichgans J, Diener HC, Kennard C) Academic Press, Amsterdam. 2003;1341–62.
2. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984; 15: 291–298.
3. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of Prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia gravis study Group. Neurology. 1998;50:1778–83.
4. Diaz-Manera J, Martinez-Hernandez E, Querol L. Long-lasting treatment effect of rituximab in MuSK myasthenia. 2012;78:189–93.
5. Lindberg C, Bokarewa M. Rituximab for severe myasthenia gravis – experience from five patients. Acta Neurol Scand. 2010;122:225–8.
6. Maddison P, McConville J, Farrugia ME, Davies N, Rose M, Norwood F, et al. The use of Rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg psychiatry. 2011;82:671–3.
7. Nowak RJ, DiCapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Therapeutic advances in neurological disorders. 2011;4:259–66.
8. Kosmidis ML, Dalakas MC. Practical considerations on the use of Rituximab in autoimmune neurological disorders. 2010;3:93–105.
9. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Clinical study group. Ann Neurol. 1997;41:789–96.
10. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Plasma exchange and intravenous immunoglobulin in autoimmune myasthenia gravis. Ann N Y Acad Sci. 1998;841:720–6.
11. Schumm F, Wiethölter H, Fateh-Moghadam A, Dichgans J. Thymektomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry. 1985;48:332–7.
12. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48:2485–92.
13. Müller-Hermelink HK, Marx A. Thymoma. Curr Opin Oncol. 2000;12:426–33.
14. Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, Dichgans J. Ocular myasthenia gravis: response to long term immunosuppressive treatment. J Neurol Neurosurg Psychiatr.1997;62:156–62.
15. Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol. 2009;256:1314–20.
16. Kupersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol. 2005;89:1330–4.
17. Anderson HJ, Churchill-Davidson HC, Richardson AT. Bronchial neoplasm with myasthenia. Prolonged apnea after administration of succinylcholine. Lancet. 1953; 2:1291–3.
18. Lambert EH, Eaton LM, Rooke ED. Defect of neuromuscular conduction associated with malignant neoplasms Am J Physiol. 1956;187:612–3.
19. Elmquist D, Lambert EH. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin Proc. 1968;43:689–713.
20. Newsom-Davis J, Lang B. The Lambert-Eaton syndrome. In: Myasthenia gravis and myasthenic syndromes (AG Engel Ed.) Oxford Univ Press, Oxford. 1999: 205–28.
21. Maddison P, Newsom-Davis. Lambert-Eaton myasthenic syndrome. In: Neuromuscular Disorders in Clinical Practice (eds. Katirji B, Kaminski HJ, Preston DC, Ruff RL, Shapiro BE) pp. 931–41.
22. Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet. 1999;353:117–8.

23. Engel AG, Ohno K. Congenital myasthenic syndromes. In: Neuromuscular Disorders (eds. R. Pourmand und Y. Harati), Williams and Wilkins, Philadelphia. 2001; 203–14.
24. Engel AG, Ohno K, Sine SM. Congenital myasthenic syndromes: progress over the past decade. Muscle Nerve. 2003; 27: 4–25.
25. Seybold ME. Thymectomy in childhood myasthenia gravis. Ann N.Y.Acad. Sci. 1998;841:731–41.
26. Drachman DB, Jones RJ, Brodsky RA. Treatment of Refractory Myasthenia: “Rebooting” with High-Dose Cyclophosphamide. Ann Neurol. 2003;53:29–34.
27. Schumm F. Therapie der myasthenen, cholinergen und insensitiven Krise. In: Neurologische Syndrome in der Intensivmedizin. (Stöhr M, Brandt T, Einhäupl M eds.) Kohlhammer-Verlag, Stuttgart. 1998;498–510.
28. Howard JF. Neurotoxicology of Neuromuscular Transmission. In: Neuromuscular Disorders in Clinical Practice (eds. Katirji B, Kaminski HJ, Preston DC, Ruff RL, Shapiro BE) pp. 964–86.
29. Schumm F, Henze T. Symptomatische Therapie bei Myasthenia gravis und anderen neuromuskulären Übertragungsstörungen. Aktuelle Neurologie. 2011;38:178–89.
30. Henze T, Janzen RWC, Schumm F, Melms A, Sieb JP, Köhler W, Heidenreich F, Tackenberg B. Immuntherapie bei Myasthenia gravis und Lambert-Eaton-Syndrom, Teil 1 und 2 Medikamentöse Immunsuppression, intravenöse Immunglobuline und Plasmaaustauschverfahren. Aktuelle Neurologie. 2010;37:505–23.